IMMP Immutep

Immutep to Participate in Upcoming Investor Conferences

Immutep to Participate in Upcoming Investor Conferences

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --   (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:

  
Jones Healthcare and Technology Innovation Conference 
Location:Las Vegas, NV 
Date:        Wednesday, 9 April 2025 
Time:4:30 pm ET 
   
The Citizens Life Sciences Conference
Location:New York, NY
Date:Thursday, 8 May 2025
Time:1:00 pm ET
 
Jefferies Global Healthcare Conference
Location: New York, NY
Date:Wednesday & Thursday, 4 & 5 June 2025
  

Additional information for the Jefferies presentation will be made available closer to the conference on the  within the Investors & Media section of Immutep’s website.

About Immutep

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit .

Australian Investors/Media:

Catherine Strong, Sodali & Co.

+61 (0)406 759 268;

U.S. Media:

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000;



EN
02/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immutep

 PRESS RELEASE

Immutep Announces Positive Update from Phase I Study of IMP761, a Firs...

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kgThe substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseasesSingle ascending dose levels will continue with 2.5, 7 and 14 mg/kgAdditional data from the Phase I to follow in second half of CY2025  SYDNEY, AUSTRALIA, June 23, 2025 ...

 PRESS RELEASE

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Pri...

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planned for presentation at a future medical meeting  SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiate...

 PRESS RELEASE

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves ...

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC)Notably, ~92% of all evaluable patients have PD-L1 TPS

 PRESS RELEASE

Immutep Quarterly Activities Report Q3 FY25

Immutep Quarterly Activities Report Q3 FY25 Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025Patient enrolment completed for the EFTISARC-NEO Phase II trial evaluating efti with radiotherapy and KEYTRUDA® in resectable soft tissue sarcomaPatient enrolment completed for the INSIGHT-003 Phase I trial evaluating efti with KEYTRUDA® and chemotherapy as first-line treatment of advanced or metastatic 1L NSCLCStrong cash position of A$146.25 mil...

 PRESS RELEASE

Immutep to Participate in Upcoming Investor Conferences

Immutep to Participate in Upcoming Investor Conferences SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --   (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:   Jones Healthcare and Technology Innovation Conference Location:Las Vegas, NV Date:        Wednesday, 9 April 2025 Time:4:30 pm ET    The Citizens Life Sciences ConferenceLocation:New York, NYDate:Thursday, 8 May 2025Time:1:00 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch